INSMED Inc. Files 8-K Report

Ticker: INSM · Form: 8-K · Filed: 2024-06-04T00:00:00.000Z

Sentiment: neutral

Topics: sec-filing, 8-k, disclosure

TL;DR

INSMED filed a routine 8-K, no major news yet.

AI Summary

On June 4, 2024, INSMED Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No specific financial figures or material events were detailed in the provided excerpt, but the filing indicates standard reporting procedures.

Why It Matters

This filing indicates INSMED Inc. is adhering to its reporting obligations with the SEC, which is standard practice for publicly traded companies.

Risk Assessment

Risk Level: low — The filing is a standard 8-K report for disclosure and exhibits, not indicating any immediate material changes or risks.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing by INSMED Inc.?

The filing is primarily for Regulation FD Disclosure and to report Financial Statements and Exhibits.

When was the earliest event reported in this 8-K filing?

The earliest event reported was on June 4, 2024.

In which state is INSMED Inc. incorporated?

INSMED Inc. is incorporated in Virginia.

What is the business address of INSMED Inc.?

The business address is 700 US Highway 202/206, Bridgewater, New Jersey 08807.

What is the telephone number for INSMED Inc.?

The telephone number is (908) 977-9900.

Filing Stats: 540 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2024-06-04 07:00:43

Key Financial Figures

Filing Documents

01 — Regulation FD Disclosure

ITEM 7.01 — Regulation FD Disclosure. Insmed Incorporated (the "Company") will host a commercial webinar on June 4, 2024 at 8:00 a.m., Eastern Time, to discuss the market outlook for the Company's three most advanced programs, ARIKAYCE (amikacin liposome inhalation suspension), brensocatib, and treprostinil palmitil inhalation powder. The live webcast will be available through the investor relations section of the Company's website. A copy of the slide presentation to be used by the Company during the conference call is attached hereto as Exhibit 99.1 and incorporated herein by reference. The information contained in this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act"), as amended, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

01 – Financial Statements and Exhibits

ITEM 9.01 – Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Insmed Incorporated June 4, 2024 Presentation. 104 Cover Page Interactive Date File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: June 4, 2024 INSMED INCORPORATED By: /s/ Michael A. Smith Name: Michael A. Smith Title: Chief Legal Officer and Corporate Secretary

View on Read The Filing